Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC, July 8, 2024...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC, June 6...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR...
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.